< Back to search results

Jeltsch Michael

Description

Finnish-German biochemist, high school diploma from Gymnasium An der Stenner (Iserlohn, Germany), undergraduate studies at the University of Hamburg, PhD from the University of Helsinki, Finland in 2003 with Kari Alitalo: discovery of the first growth factors for lymphatic vessels: VEGF-C and VEGF-D. Since 2020 associate professor at the Faculty of Pharmacy, University of Helsinki. Experience in three biotech startups with several patents and three drugs in clinical trials: OPT-302/sozinibercept (developer, phase III), VGX-100 and Lymfactin (co-developer, up to phase I and II, respectively). Currently working on novel and sustainable protein expression systems.

Affiliations

University of Helsinki
Associate Professor in Pharmaceutical Protein Drug Research
Drug Research Program
2020 - present
Source: ORCID
University of Helsinki
Group leader
Translational Cancer Biology Program/Individual Drug Therapy Research Program
2013 - 2020
Source: ORCID
Wihuri Research Institute
Postdoctoral Fellow
2013
Source: ORCID
University of Helsinki
Postdoctoral Fellow
Molecular/Cancer Biology Laboratory
2003 - 2013
Source: ORCID
Vegenics Ltd/Circadian Technologies via Licentia Oy (now Opthea)
Contract Researcher
2007 - 2011
Source: ORCID
Lymphatix Oy (acquired by Ark Therapeutics)
Researcher
2006 - 2007
Source: ORCID
Helsinki University Licencing Ltd./Licentia Ltd.
Contract Researcher
1999 - 2005
Source: ORCID
University of Helsinki
Graduate Student
Molecular/Cancer Biology Laboratory
1996 - 2002
Source: ORCID
Heinrich-Pette-Institut Leibniz-Institut fur Experimentelle Virologie
Research Assistant
Group Hans Will
1994 - 1995
Source: ORCID

Education (4)

PhD
University of Helsinki
MSc
University of Helsinki
BSc/"Vordiplom"
University of Hamburg
Baccalaureate
Gymnasium An der Stenner

Publications (55)

2023
The Relationship between the Secondary Vascular System and the Lymphatic Vascular System in Fish
DOI
10.20944/preprints202312.2119.v1
2022
Expansion and collapse of VEGF diversity in major clades of the animal kingdom
DOI
10.1101/2022.09.19.507521
Lymphatic-to-blood vessel transdifferentiation in zebrafish
DOI
10.1038/s44161-022-00073-1

Granted funding (1)

Development of a biotherapeutical to counter cancer “resistance” to presently used anti- angiogenic drugs
Research Council of Finland
2013 - 2018

Activities and awards (9)

Conference presentation
Drug-induced lymphangiogenesis
2022
International collaboration: No
Other activity
The Proteolytic Activation of Vascular Endothelial Growth Factors
2021
International collaboration: No
Reviewer of a scientific journal
Reviewer
SpringerNature
2021
International collaboration: No